Previous 10 | Next 10 |
home / stock / chexf / chexf news
OTTAWA, June 22, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV)(“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting i...
Avivagen ( OTCPK:CHEXF ) has signed a distribution agreement for OxC-beta Livestock in Thailand with FAITH (Feed and Ingredients Technology Hub), a member of the BIS Group of Companies. More news on: Avivagen, Inc., Healthcare stocks news, Read more ...
OTTAWA, Ontario, June 13, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV)(“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely sup...
Avivagen ( OTCPK:CHEXF ): Q2 net loss of $1.02M More news on: Avivagen, Inc., Earnings news and commentary, Consumer stocks news, , Read more ...
OTTAWA, June 05, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSX-V:VIV) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting...
Avivagen ( OTCPK:CHEXF ) has made its first sale of Vivamune Health Chews into the Chinese market through an arrangement with Pawllion Inc. Registration in China is anticipated to take 12-14 months. More news on: Avivagen, Inc., Healthcare stocks news, Read more ...
OTTAWA, June 01, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV)(“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting i...
OTTAWA, May 30, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting i...
Avivagen ( OTCPK:CHEXF ) has retained Meyenberg International Group (MIG) as its agent to help the Company pursue regulatory approval for the use of Avivagen’s OxC-beta in livestock in Mexico. The regulatory process may require approx. one year following of the signing of this agree...
OTTAWA, May 25, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV)(“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting im...
News, Short Squeeze, Breakout and More Instantly...
Phoenix, Arizona--(Newsfile Corp. - October 2, 2019) - The Stock Day Podcast welcomed Avivagen Inc. (CHEXF) ("the Company"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune f...
PHOENIX, May 13, 2019 (GLOBE NEWSWIRE) -- Uptick Newswire Stock Day Podcast welcomed Avivagen Inc. (CHEXF) , a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, pro...
OTTAWA, March 06, 2019 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”) reported today its unaudited financial results for Q1 2019. For the three-month period ended January 31, 2019, the Corporation reported revenues of $322,125 &...